By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Athenagen Inc. 

Name change to Comentis, Inc.Press releases archived for reference only.
280 Utah Avenue, Suite 275
South San Francisco  California  94080  U.S.A.
Phone: 650-616-1920 Fax: 650-649-1819


SEARCH JOBS








Company News
Athenagen Inc. Announces Name Change To CoMentis 2/20/2007 10:34:13 AM
Athenagen Inc.'s Eye Drop Therapy For AMD Is Safe And Well Tolerated In Phase I Study 1/31/2007 10:50:54 AM
Athenagen Inc. Initiates Phase II Clinical Trial In Alzheimer's Disease 12/13/2006 11:28:37 AM
Athenagen Inc. Expands Leadership Team With Two Seasoned Drug Development Professionals 10/23/2006 11:22:37 AM
Athenagen Inc. Raises $50 Million In Series B Financing 9/28/2006 8:46:09 AM
The Day In Review: Amgen (AMGN) Gets Approval For Vectibix 9/27/2006 6:34:15 PM
Athenagen Inc. Initiates Clinical Development Of Its Anti-Angiogenic Eye Drop Therapy For AMD 8/21/2006 9:23:37 AM
Athenagen Inc. Completes Merger With Zapaq, Inc. 8/14/2006 10:19:54 AM
Athenagen Inc. And Zapaq, Inc. To Merge 7/10/2006 12:01:27 PM
Athenagen Inc. Advances Angiogenesis Drug To Clinical Testing 6/21/2006 10:41:42 AM
12
//-->